Biovitrum completes acquisition of Cambridge Biotechnology Ltd
The company's projects are at an advanced stage, with one currently in the clinical phase and another expected to enter Phase I in 2006. As a Biovitrum subsidiary, CBT will continue to operate as an autonomous and innovative R&D unit, based in Cambridge, in the UK.
"The acquisition of CBT is in line with our core business-development strategy and is significant for Biovitrum. We are developing our therapeutic base and this acquisition provides us with a direct connection into one of Europe's most interesting research and biotech clusters," says Mats Pettersson, CEO of Biovitrum.
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.